Literature DB >> 21412493

Management of stage IV rectal cancer: palliative options.

Sean M Ronnekleiv-Kelly1, Gregory D Kennedy.   

Abstract

Approximately 30% of patients with rectal cancer present with metastatic disease. Many of these patients have symptoms of bleeding or obstruction. Several treatment options are available to deal with the various complications that may afflict these patients. Endorectal stenting, laser ablation, and operative resection are a few of the options available to the patient with a malignant large bowel obstruction. A thorough understanding of treatment options will ensure the patient is offered the most effective therapy with the least amount of associated morbidity. In this review, we describe various options for palliation of symptoms in patients with metastatic rectal cancer. Additionally, we briefly discuss treatment for asymptomatic patients with metastatic disease.

Entities:  

Keywords:  Endorectal stenting; Laser ablation; Malignant bleeding; Malignant obstruction; Palliative therapy; Rectal cancer

Mesh:

Year:  2011        PMID: 21412493      PMCID: PMC3051134          DOI: 10.3748/wjg.v17.i7.835

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  131 in total

1.  Multivariate analysis of morbidity and mortality from the initial surgical management of obstructing carcinoma of the colon.

Authors:  I M Leitman; J D Sullivan; D Brams; J J DeCosse
Journal:  Surg Gynecol Obstet       Date:  1992-06

2.  Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome.

Authors:  B Cady; R L Jenkins; G D Steele; W D Lewis; M D Stone; W V McDermott; J M Jessup; A Bothe; P Lalor; E J Lovett; P Lavin; D C Linehan
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

3.  Initial presentation with stage IV colorectal cancer: how aggressive should we be?

Authors:  S A Rosen; J F Buell; A Yoshida; S Kazsuba; R Hurst; F Michelassi; J M Millis; M C Posner
Journal:  Arch Surg       Date:  2000-05

4.  Outcomes of total pelvic exenteration for colorectal cancer.

Authors:  Minoru Nishio; Chohei Sakakura; Tomoyuki Nagata; Atsushi Miyashita; Takuo Hamada; Hisashi Ikoma; Takeshi Kubota; Masayoshi Nakanishi; Akio Kimura; Daisuke Ichikawa; Syoujirou Kikuchi; Hitoshi Fujiwara; Kazuma Okamoto; Toshiya Ochiai; Yukihito Kokuba; Hiroki Taniguchi; Teruhisa Sonoyama; Akeo Hagiwara; Eigo Otsuji
Journal:  Hepatogastroenterology       Date:  2009 Nov-Dec

5.  Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection.

Authors:  S Nagakura; Y Shirai; Y Yamato; N Yokoyama; T Suda; K Hatakeyama
Journal:  J Am Coll Surg       Date:  2001-08       Impact factor: 6.113

6.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma.

Authors:  Tommaso Claudio Mineo; Vincenzo Ambrogi; Giuseppe Tonini; Patrizio Bollero; Mario Roselli; Davide Mineo; Italo Nofroni
Journal:  J Am Coll Surg       Date:  2003-09       Impact factor: 6.113

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma.

Authors:  Masayoshi Inoue; Mitsunori Ohta; Keiji Iuchi; Akihide Matsumura; Kan Ideguchi; Tsutomu Yasumitsu; Katsuhiro Nakagawa; Kenjiro Fukuhara; Hajime Maeda; Shin-ichi Takeda; Masato Minami; Yuko Ohno; Hikaru Matsuda
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

10.  Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases.

Authors:  A E van der Pool; J H de Wilt; Z S Lalmahomed; A M Eggermont; J N Ijzermans; C Verhoef
Journal:  Br J Surg       Date:  2010-03       Impact factor: 6.939

View more
  15 in total

1.  Modified simultaneous integrated boost radiotherapy for an unresectable huge refractory pelvic tumor diagnosed as a rectal adenocarcinoma.

Authors:  Takuma Nomiya; Hiroko Akamatsu; Mayumi Harada; Ibuki Ota; Yasuhito Hagiwara; Mayumi Ichikawa; Misako Miwa; Shouhei Kawashiro; Motohisa Hagiwara; Masahiro Chin; Eiji Hashizume; Kenji Nemoto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Palliation of gastrointestinal obstruction.

Authors:  Golda Tradounsky
Journal:  Can Fam Physician       Date:  2012-06       Impact factor: 3.275

3.  A temporary self-expanding metallic stent for malignant colorectal obstruction.

Authors:  Xiao-Li Ding; Yong-Dong Li; Rui-Min Yang; Fen-Bao Li; Ming-Qiu Zhang
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

4.  Near-Infrared Fluorescent Endoscopic Image-Guided Photothermal Ablation Therapy of Colorectal Cancer Using Dual-Modal Gold Nanorods Targeting Tumor-Infiltrating Innate Immune Cells in a Transgenic TS4 CRE/APC loxΔ468 Mouse Model.

Authors:  Elias Gournaris; Wooram Park; Soojeong Cho; David J Bentrem; Andrew C Larson; Dong-Hyun Kim
Journal:  ACS Appl Mater Interfaces       Date:  2019-06-04       Impact factor: 9.229

Review 5.  The management of rectal cancer with synchronous liver metastases: a modern surgical dilemma.

Authors:  A A P Slesser; A Bhangu; G Brown; S Mudan; P P Tekkis
Journal:  Tech Coloproctol       Date:  2012-09-26       Impact factor: 3.781

6.  The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.

Authors:  Tony Reid; Bryan Oronsky; Nacer Abrouk; Scott Caroen; Pedro Cabrales
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

7.  Influence of hospital type on survival in stage IV colorectal cancer.

Authors:  Nobuaki Hoshino; Suguru Hasegawa; Koya Hida; Kenji Kawada; Ryosuke Okamura; Madoka Hamada; Yoshinori Munemoto; Yoshiharu Sakai; Masahiko Watanabe
Journal:  Int J Colorectal Dis       Date:  2016-06-03       Impact factor: 2.571

8.  Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients.

Authors:  Baskar Subramani; Chithra Ramanathan Pullai; Kohila Krishnan; Sheela Devi Sugadan; Xuewen Deng; Terunuma Hiroshi; Kananathan Ratnavelu
Journal:  Biomed Rep       Date:  2014-03-26

Review 9.  Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.

Authors:  Renato Costi; Francesco Leonardi; Daniele Zanoni; Vincenzo Violi; Luigi Roncoroni
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

10.  Impact of Treatment Coordination on Overall Survival in Rectal Cancer.

Authors:  Kevin Biju; George Q Zhang; Miloslawa Stem; Rebecca Sahyoun; Bashar Safar; Chady Atallah; Jonathan E Efron; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2021-01-23       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.